{
    "clinical_study": {
        "@rank": "40314", 
        "arm_group": [
            {
                "arm_group_label": "PLD-contained VDCLD regimen", 
                "arm_group_type": "Experimental", 
                "description": "PLD 36 mg/m2 ivdrip over 60 minutes( d1\u300115),VCR 1.4mg/m iv(d1\uff0c8\uff0c15\uff0c22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19\uff5e28),Dex10mg ivdrip (d1\uff5e28)."
            }, 
            {
                "arm_group_label": "DNR-contained VDCLD regimen", 
                "arm_group_type": "Active Comparator", 
                "description": "DNR 45 mg/m2 ivdrip over 60 minutes(d1\uff5e3),VCR 1.4mg/m2 iv(d1\uff0cd8\uff0cd15\uff0cd22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19\uff5e28),Dex10mg ivdrip(d1\uff5e28)."
            }
        ], 
        "brief_summary": {
            "textblock": "To determine, compared with Daunorubicin(DNR), whether Pegylated liposomal doxorubicin (PLD)\n      inducing higher complete remission (CR) rate, in untreated primary ALL adult patients with\n      VDCLD regimen induction therapy. Second, to determine, compared with the DNR, whether\n      chemotherapy containing PLD with a higher response rates and greater safety in adult ALL"
        }, 
        "brief_title": "Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Lymphoblastic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter, open, non-intervention clinical study, with estimated\n      enrollment of 200 newly diagnosed adult ALL patients. After the first course of treatment\n      administered with PLD-contained or DNR-contained VDCLD regimen, CR rate and changes of\n      leukemia stem cells in bone marrow, was evaluated; the safety of these chemotherapy was also\n      evaluated.\n\n      Study Patients:\n\n      Patients included in this study should be untreated with ALL previously, being in line with\n      the inclusion criteria and exclusion criteria.\n\n      Dosage and Administration:\n\n      PLD-contained VDCLD regimen\uff1aPLD 36 mg/m2 ivdrip over 60 minutes( d1\u300115),VCR 1.4mg/m\n      iv(d1\uff0c8\uff0c15\uff0c22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19\uff5e28),Dex10mg ivdrip\n      (d1\uff5e28).\n\n      DNR-contained VDCLD regimen\uff1aDNR 45 mg/m2 ivdrip over 60 minutes(d1\uff5e3),VCR 1.4mg/m2\n      iv(d1\uff0cd8\uff0cd15\uff0cd22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19\uff5e28),Dex10mg\n      ivdrip(d1\uff5e28).\n\n      Endpoints:\n\n      Primary endpoint: The primary endpoint of the study was complete remission (CR) rates after\n      the first course of regimen. The proportion of patients achieved CR was evaluated, after the\n      first course of induction chemotherapy administered with PLD-contained or DNR-contained\n      VDCLD regimen Secondary endpoint: The change of leukemia stem cells in bone marrow, was\n      evaluated before and after administered with PLD-contained or DNR-contained VDCLD regimen.\n\n      Safety Assessment:\n\n      In order to adjust the treatment strategy and ensure patients' safety effectively, routine\n      blood test, transaminases, and creatinine was monitored on time during the period, while\n      lung CT and ECG was performed based on clinical need. Possible adverse reactions and\n      tolerability during treatment, such as gastrointestinal reactions, cardiac function, as well\n      as discontinuation ratio due to side effects or tolerability of PLD, was recorded.\n\n      Statistical Analysis:\n\n      All the calculations were performed with the SPSS statistical software. The continuous\n      variables were performed with T test; categorical variables were performed with\u03c72 test.\n      After acceptance of various observation records sheets, data were unified processed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Eligible men or women were age over 14\uff0cbut less than 60 years;\n\n        Eastern Cooperative Oncology Group performance status of 0 to2;\n\n        Diagnosed with ALL (WHO classification, the primitive cells \u2265 20%);\n\n        Previous untreated ALL patients had not received chemotherapy before (excluding\n        dexamethasone, prednisone, and hydroxyurea). History of receiving blood transfusion,\n        hematopoietic growth factors, vitamin, and palliative measures such as leukocyte removal,\n        dexamethasone, prednisone, hydroxyurea (0.5-3g daily, more than three days) is allowed;\n\n        The levels of LSCs in bone marrow were measured with flow cytometry before treatment;\n\n        Subjects must be able to provide written informed consent.\n\n        Exclusion Criteria:\n\n        Mixed type of AL patients;\n\n        Clinically significant active infections;\n\n        Nursing (breastfeeding) or intending to be nursing during the study\uff1b\n\n        Pregnancy, or intending to become pregnant during the study;\n\n        Patients with cardiac dysfunction currently (especially congestive heart failure) or\n        history of congestive heart failure;\n\n        Patients with severe liver failure (ALT \u2265 5 times the upper limit of normal (ULN), total\n        bilirubin \u2265 3mg/dL)\n\n        Patients with renal insufficiency, creatinine clearance <30ml/min, creatinine clearance\n        rate is calculated as follows: Men: Ccr (ml / min) = (140 - age) \u00d7 weight (kg) / [0.8136 \u00d7\n        serum creatinine (\u03bcmol / L )] female: Ccr (ml / min) = (140 - age) \u00d7 weight (kg) \u00d7 0.85 /\n        [0.8136 \u00d7 serum creatinine (\u03bcmol / L)];\n\n        Patients did not or will not participate in other trials of drugs 30 days before or 90\n        days after the beginning of this study,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070523", 
            "org_study_id": "ChangzhouJP"
        }, 
        "intervention": {
            "arm_group_label": [
                "PLD-contained VDCLD regimen", 
                "DNR-contained VDCLD regimen"
            ], 
            "intervention_name": "VDCLD regimen", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Daunorubicin", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 23, 2014", 
        "location": {
            "contact": {
                "email": "13560512702@139.com", 
                "last_name": "Yang Zhi gang", 
                "phone": "+86 13560512702"
            }, 
            "facility": {
                "address": {
                    "city": "Zhanjiang", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "524000"
                }, 
                "name": "Department of Hematology, Affiliated Hospital of Guangdong Medical College"
            }, 
            "investigator": {
                "last_name": "Zhi gang Yang", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells", 
        "overall_contact": {
            "email": "13560512702@139.com", 
            "last_name": "Zhi gang Yang", 
            "phone": "+86 13560512702"
        }, 
        "overall_official": {
            "affiliation": "Guangdong Medical College", 
            "last_name": "Zhigang Yang", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study was complete remission (CR) rates after the first course of regimen. The proportion of patients achieved CR was evaluated, after the first course of induction chemotherapy administered with PLD-contained or DNR-contained VDCLD regimen", 
            "measure": "Complete remission (CR) rates after the first course of regimen", 
            "safety_issue": "Yes", 
            "time_frame": "3 years after the last enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070523"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change of leukemia stem cells in bone marrow, was evaluated before and after administered with PLD-contained or DNR-contained VDCLD regimen.", 
            "measure": "The change of leukemia stem cells in bone marrow", 
            "safety_issue": "Yes", 
            "time_frame": "3 years after the last enrollment"
        }, 
        "source": "Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}